HCCR-1-interacting molecule "deleted in polyposis 1" plays a tumor-suppressor role in colon carcinogenesis.

BACKGROUND & AIMS Human cervical cancer oncogene (HCCR-1) has appeared to act as a negative regulator of p53 and contributes to tumorigenesis of various organs including the colon. We identified the HCCR-1 binding protein deleted in polyposis 1 (DP1) and accessed the role of HCCR-1 and DP1 in colon tumorigenesis. METHODS Yeast 2-hybrid was used to identify HCCR-1 interacting proteins. Various molecular biological approaches were used to examine the expression profile of HCCR-1 and DP1, subcellular localization, epitope mapping, the biological role of DP1, and the serum HCCR-1 level. Loss of heterozygosity frequency around DP1 also was examined. RESULTS We identified that HCCR-1 interacted with DP1. These 2 proteins colocalized in mitochondria but the expression of HCCR-1 showed negative correlation with that of DP1 in colorectal cancer (CRC). DP1 played a tumor-suppressor role in colon tumorigenesis (ie, DP1-transfected RKO cells showed growth inhibition, apoptosis, decreased telomerase activity, and up-regulation of p53). These phenomena were reversed when HCCR-1 was overexpressed. Loss of heterozygosity around the DP1 gene was observed frequently (50%) in CRCs. We examined the use of serum HCCR-1 in CRC patients. The sensitivity of HCCR-1 (76.0%) for detecting CRC was proven to be much higher than that of CA19-9 (32.0%). CONCLUSIONS DP1 plays a tumor-suppressor role in CRC. DP1 and HCCR-1 are supposed to regulate each other negatively by interaction, but further study is required to get better insight into the biological significance of the interaction.

[1]  S. Hwang,et al.  Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization , 2003, Oncogene.

[2]  C. Greider.  Telomerase and telomere-length regulation: lessons from small eukaryotes to mammals. , 1993, Cold Spring Harbor symposia on quantitative biology.

[3]  A. Feinberg,et al.  Microallelotyping defines the sequence and tempo of alleiic losses at tumour suppressor gene loci during colorectal cancer progression , 1995, Nature Medicine.

[4]  K. Kinzler,et al.  Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. , 1991, Science.

[5]  M. Leppert,et al.  Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps , 1998, Nature Genetics.

[6]  G. Pendl,et al.  The murine homolog of TB2/DP1, a gene of the familial adenomatous polyposis (FAP) locus. , 1996, Gene.

[7]  Margaret Robertson,et al.  Identification and characterization of the familial adenomatous polyposis coli gene , 1991, Cell.

[8]  R. Jemmerson,et al.  Mapping epitopes on a protein antigen by the proteolysis of antigen-antibody complexes. , 1986, Science.

[9]  N. Carlomagno,et al.  Three submicroscopic deletions at the APC locus and their rapid detection by quantitative-PCR analysis , 1999, European Journal of Human Genetics.

[10]  P. Polakis.  The adenomatous polyposis coli (APC) tumor suppressor. , 1997, Biochimica et biophysica acta.

[11]  J. Wands,et al.  The Human Cervical Cancer Oncogene Protein Is a Biomarker for Human Hepatocellular Carcinoma , 2004, Cancer Research.

[12]  J. McPherson,et al.  Identification of deletion mutations and three new genes at the familial polyposis locus , 1991, Cell.

[13]  A. Jauch,et al.  Familial adenomatous polyposis: A submicroscopic deletion at the APC locus in a family with mentally normal patients , 1996, Human Genetics.

[14]  J. Bonnefoy,et al.  Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. , 1999, Cytometry.

[15]  S. Shin,et al.  Transgenic mouse model for breast cancer: induction of breast cancer in novel oncogene HCCR-2 transgenic mice , 2004, Oncogene.

[16]  C. Zwieb,et al.  Isolation and characterization of a cDNA clone encoding the 19 kDa protein of signal recognition particle (SRP): expression and binding to 7SL RNA. , 1988, Nucleic acids research.

[17]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[18]  M. Leppert,et al.  A CA repeat 30-70 KB downstream from the adenomatous polyposis coli (APC) gene. , 1991, Nucleic acids research.

[19]  N. Crawford,et al.  Tumor markers and colorectal cancer: Utility in management , 2003, Journal of surgical oncology.

[20]  R. Weinberg,et al.  Tumor suppressor genes. , 1991, Science.

[21]  A. Strasser,et al.  Ionizing Radiation and Chemotherapeutic Drugs Induce Apoptosis in Lymphocytes in the Absence of FAS or Fadd/Mort1 Signaling Implications for Cancer Therapy , 2000 .

[22]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[23]  S. Galandiuk,et al.  What’s New with Tumor Markers for Colorectal Cancer? , 2000, Digestive Surgery.

[24]  A. Scarpa,et al.  Chromosome 5 allelic losses are early events in tumours of the papilla of Vater and occur at sites similar to those of gastric cancer. , 1998, British Journal of Cancer.

[25]  H. Binz,et al.  Epitope mapping by chemical modification of free and antibody-bound protein antigen. , 1987, Science.

[26]  C. Haglund,et al.  CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. , 2002, Anticancer research.

[27]  E. Fearon.  Genetic alterations underlying colorectal tumorigenesis. , 1992, Cancer surveys.

[28]  W. Foulkes,et al.  Familial Adenomatous Polyposis , 2006, The American Journal of Gastroenterology.

[29]  K. Tanaka,et al.  Familial polyposis: recent advances. , 1995, Critical reviews in oncology/hematology.